PA
MDGL icon

Perceptive Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Perceptive Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300,000
Closed -$87.1M – 102
2022
Q4 		$87.1M Buy
+300,000
New +$29.3M 2.45% 10

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Perceptive Advisors's MDGL Position: Q2 2025 in Review

Perceptive Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 46,500 shares — an estimated $15.4M sold.

Perceptive Advisors first reported a position in MDGL in Q2 2013 and held it in 18 quarters. The position peaked at $212M in Q4 2022. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Perceptive Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Perceptive Advisors sold 46,500 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $15.4M.
  • Perceptive Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Perceptive Advisors's Madrigal Pharmaceuticals position peaked at $212M in Q4 2022.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.